Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.59%
#2 Venom Venom +24.69%
#3 Decred Decred +10.82%
#4 DexNet DexNet +7.57%
#5 TRIA TRIA +6.91%
#6 Status Status +6.45%
#7 Wibx Wibx +5.98%
#8 SkyAI SkyAI +5.16%
#9 Talus Network Talus Network +4.56%
#10 Audiera Audiera +4.30%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Synthetic Biologics, Inc.

SYN
Classificação em ações #30606
Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on... Synthetic Biologics, Inc. is a clinical-stage biotechnology firm focused on creating treatments for illnesses with significant unmet medical demands. Among its leading product candidates is SYN-004, engineered to neutralize common intravenous beta-lactam antibiotics within the digestive system. This aims to safeguard the gut microbiome, prevent Clostridium difficile infections (CDI), curb the proliferation of harmful bacteria, combat antimicrobial resistance (AMR), and mitigate acute graft-versus-host-disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key asset is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, intended to address both localized gastrointestinal and systemic conditions. The company is also advancing VCN-01, a therapeutic candidate for various cancers, including pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Additional clinical-stage programs include SYN-006, targeting the prevention of aGVHD and infections from carbapenem-resistant enterococci; SYN-007, designed to avert antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for the prevention and treatment of whooping cough (pertussis); and VCN-11, another cancer therapeutic. Synthetic Biologics maintains partnerships with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis supports a Phase 1b/2a clinical trial for SYN-004. The company's main operations are based in Rockville, Maryland.
Preço da ação
$1.02
Última sincronização: 2022-10-13
Valor de mercado
$16.16M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Synthetic Biologics, Inc. (SYN)

Categoria

Healthcare
Histórico de preços das ações de Synthetic Biologics, Inc. (SYN)
Preço de fecho mais alto: $1.05 em 2022-10-01

Preço de fecho mais baixo: $838.79 em 2012-02-01
Histórico de preços das ações da Synthetic Biologics, Inc. de 2012 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2022 -66.74%
2021 -13.70%
2020 -18.74%
2019 -28.68%
2018 -96.72%
2017 -33.18%
2016 -66.52%
2015 62.87%
2014 20.10%
2013 -27.54%
2012 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $527.89 35.09%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $996.61 51.72%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $116.13 -20.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $735.86 6.07%
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $257.75 14.92%
BE